Surgical device start-up Protego Medical launches
Medical technology start-up Protego Medical formally launched yesterday and announced the appointment of its first CEO.
Protego is developing a device to provide sternal protection during cardiac surgery. The company was formed yesterday with $2 million in seed funding from Australia’s Medical Research Commercialisation Fund (MRCF).
The company is being led up by new CEO Pablo Solis, who will draw on his 17 years’ worth of product development and manufacturing experience.
During his career, Solis has held roles at companies including Fisher & Paykel, ResMed, Ventracor and Finisar.
Protego’s sternal protection technology was originally developed by Melbourne-based cardiothoracic surgeon Dr Randall Moshinsky.
It is designed to overcome the significant issue of bleeding from the divided sternum during cardiothoracic surgery, while also reducing trauma to the sternum from use of the sternal retractor.
“This simple technology has excellent potential to both reduce blood loss and also protect the sternum during heart operations,” Solis said. “[Around] 1.2 million cardiac operations take place each year in the USA and Europe and sternal bleeding and trauma can greatly impede the recovery of patients.”
Robotic laboratory to fast-track drug invention, trials and commercialisation
The lab will house an automated system for high-throughput X-ray crystallography, often referred...
Bio-inspired robotic bird has stable flight in its sights
The nankeen kestrel is among the most stable fliers in the avian world. Using motion capture...
Protecting particles that carry mRNA in dry vaccine patches
Combining expertise from RMIT University, MIT and Harvard Medical School, scientists set out to...
